Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare, serious condition that can lead to excessive bleeding in fetuses and newborns. It is caused by a mismatch between an expectant mother and her fetus in a specific human platelet antigen, most commonly HPA-1. There is currently no approved therapy for the prevention or treatment of patients with FNAIT.
The stock we are bringing to your attention today is that of Rallybio Corp. (RLYB), a clinical-stage biotechnology company developing therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com